Sunshine Biopharma (SBFM) Cash from Operations Growth (1y) (2011 - 2026)
Sunshine Biopharma (SBFM) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn | 27.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.91% |
| Mar 31, 2026 | -22.25% |
| Dec 31, 2025 | 52.54% |
| Sep 30, 2025 | 46.35% |
| Jun 30, 2025 | 71.77% |
| Mar 31, 2025 | 46.78% |
| Dec 31, 2024 | -26.60% |
| Sep 30, 2024 | -196.66% |
| Jun 30, 2024 | -21.17% |
| Mar 31, 2024 | -72.16% |
| Dec 31, 2023 | -19.72% |
| Sep 30, 2023 | 59.31% |
| Jun 30, 2023 | -558.42% |
| Mar 31, 2023 | -41.86% |
| Dec 31, 2022 | -619.81% |
| Sep 30, 2022 | -87.04% |
| Jun 30, 2022 | 7.28% |
| Mar 31, 2022 | -338.60% |
| Dec 31, 2021 | 26.33% |
| Sep 30, 2021 | -398.28% |